Unknown

Dataset Information

0

Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease.


ABSTRACT: Early identification of Alzheimer's disease (AD) risk factors would aid development of interventions to delay the onset of dementia, but current biomarkers are invasive and/or costly to assess. Validated plasma biomarkers would circumvent these challenges. We previously identified the kinase DYRK1A in plasma. To validate DYRK1A as a biomarker for AD diagnosis, we assessed the levels of DYRK1A and the related markers brain-derived neurotrophic factor (BDNF) and homocysteine in two unrelated AD patient cohorts with age-matched controls. Receiver-operating characteristic curves and logistic regression analyses showed that combined assessment of DYRK1A, BDNF and homocysteine has a sensitivity of 0.952, a specificity of 0.889 and an accuracy of 0.933 in testing for AD. The blood levels of these markers provide a diagnosis assessment profile. Combined assessment of these three markers outperforms most of the previous markers and could become a useful substitute to the current panel of AD biomarkers. These results associate a decreased level of DYRK1A with AD and challenge the use of DYRK1A inhibitors in peripheral tissues as treatment. These measures will be useful for diagnosis purposes.

SUBMITTER: Janel N 

PROVIDER: S-EPMC5537644 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease.

Janel N N   Alexopoulos P P   Badel A A   Lamari F F   Camproux A C AC   Lagarde J J   Simon S S   Feraudet-Tarisse C C   Lamourette P P   Arbones M M   Paul J L JL   Dubois B B   Potier M C MC   Sarazin M M   Delabar J M JM  

Translational psychiatry 20170620 6


Early identification of Alzheimer's disease (AD) risk factors would aid development of interventions to delay the onset of dementia, but current biomarkers are invasive and/or costly to assess. Validated plasma biomarkers would circumvent these challenges. We previously identified the kinase DYRK1A in plasma. To validate DYRK1A as a biomarker for AD diagnosis, we assessed the levels of DYRK1A and the related markers brain-derived neurotrophic factor (BDNF) and homocysteine in two unrelated AD pa  ...[more]

Similar Datasets

| S-EPMC4548441 | biostudies-other
| S-EPMC4930124 | biostudies-literature
| S-EPMC9740390 | biostudies-literature
| S-EPMC6697226 | biostudies-literature
| S-EPMC6953632 | biostudies-literature
2009-01-30 | GSE14522 | GEO
| S-EPMC6952086 | biostudies-literature
| S-EPMC8095509 | biostudies-literature
2009-01-23 | GSE14499 | GEO
| S-EPMC7541946 | biostudies-literature